Korean Market
OWNR
Samjin Pharmaceutical
★

Jo Ui-hwan and Special Relations Extend Stock Pledge Agreements; Holding Ratio Increases Due to Share Cancellation

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical Vice President Jo Gyu-hyeong Plans to Receive 135,000 Shares as Gift from Jo Ui-hwan, Ownership to Rise to 4.20%

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical CEO Jo Gyu-seok to Receive 135,000 Shares as Gift from Jo Ui-hwan

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical's largest shareholder Jo Ui-hwan plans to gift 270,000 shares to family, reducing stake from 6.30% to 4.28%

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical CEO Choi Ji-hyun Reports Minor Change in Stake via Open Market Trades

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical Officer Shin Seung-won Increases Shareholding by 400 Shares via Open Market Purchase

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical Unregistered Executive Park Chang-ik Increases Stake via Open Market Purchase - Positive Signal for Stock Price

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharmaceutical Executive Park Chang-ik Buys 2,000 Shares, Slight Stake Increase and Share Cancellation Positive

 
OWNR
Samjin Pharmaceutical
★

Samjin Pharma Major Shareholder Choe Seung-ju Reports Changes in Pledge Contracts, No Change in Stake or Voting Rights (Neutral)

 
EXCH
Samjin Pharmaceutical
★

Samjin Pharmaceutical Discloses Corporate Governance Report: Share Buyback of 580,000 Shares, Stable Dividend Policy, and Ongoing Governance Improvements

 
OWNR
Samjin Pharmaceutical
★★

Hana Pharm and related party drastically reduce stake in Samjin Pharmaceutical from 8.33% to 0.75%... On-market sale for simple investment purpose puts downward pressure on stock

 
OWNR
Samjin Pharmaceutical
★★

Hana Pharm reduces stake in Samjin Pharmaceutical from 8.33% to 1.22% (sells 995,198 shares on market)

 
OWNR
Samjin Pharmaceutical
★

Executive Sangjin Kim increases stake to 0.08% via open market purchase of 3,000 shares at KRW 17,869

 
OWNR
Samjin Pharmaceutical
★

Non-Registered Director Shin Seung-won Acquires 600 Common Shares via Open Market (0.00% Stake)

 
PERI
Samjin Pharmaceutical
★

Samjin Pharmaceutical Q1 2026: Sales -3.9%, Operating Profit -25.8%, R&D Investment Expands (12.24% of Sales)